Rahul Aggarwal

University of California
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (109)

Plasma concentration for copanlisib (BAY 80-6946). Plasma concentration of copanlisib (BAY 80-6946) was measured in samples from nine patients collected on cycle 1 day 15 before infusion (pre-dose) and at 0.5, 1, 2, 4, 6, 8, and 24 hours after infusion. Eight patients received copanlisib 45 mg and one patient received 30 mg. The time to the maximum concentration of copanlisib when administered in combination with rucaparib ranged between 0.5 and 4 hours. The mean terminal half-life was 41.4 ± 56.7 hours. The mean clearance was 32,656 ± 18,164 mL/hour. These parameters are consistent with historical PK parameters of copanlisib.

Year:

2025

Purpose: Metastatic castration-resistant prostate cancer with homologous recombination (HR) deficiency (HRD) is sensitive to PARP inhibitors (PARPi). PI3K inhibitors (PI3Ki) sensitize to PARPi by disrupting HR in preclinical models. This phase Ib/II study investigated copanlisib (Copa; pan–class I PI3Ki) and rucaparib (R). Patients and Methods: Eligible patients had metastatic castration-resistant prostate cancer treated with ≥1 androgen receptor inhibitor and taxanes. Phase I followed a standard 3 + 3 dose-escalation design (rucaparib 400–600 mg orally twice a day; Copa 45–60 mg i.v. on days 1, 8, and 15). Primary goal of phase I was to establish MTD and the recommended phase II dose. The primary endpoint of phase II was PSA50 response rate. Results: Thirteen patients enrolled had a median age of 64 (55–78) years and PSA was 11.7 ng/mL (0.018–2,101). Seven patients received taxanes, and one patient received PARPi. Eight patients had HRD+ tumors [ BRCA2 (four), BRCA1 (one), RAD51C (one), CDK12 (one), and FANCA (one)] and three had PTEN loss. There were two dose-limiting toxicities in dose level 1 (rucaparib 400 mg twice a day; Copa 45 mg on days 1, 8, and 15): grade 3 rash and aspartate aminotransferase/alanine aminotransferase elevation. Treatment-related adverse events ≥ grade 2 included leukopenia (54%), anemia (38%), rash (30%), fatigue (23%), and neutropenia (23%). Six patients were treated at dose level –1 without dose-limiting toxicities, which was established as the recommended phase II dose (rucaparib 400 mg twice a day + Copa 45 mg on day 1/15). Among patients with HRD+, one had confirmed partial response and three had stable disease by RECIST, including one patient treated with prior PARPi, and three patients had PSA50 responses (23%). Conclusions: Copa/R had an acceptable safety profile with a signal of efficacy supporting future studies of PARPi with PI3Ki. Significance: Gene alterations in the PI3K and HR pathways are common in prostate cancer. Based on preclinical studies, the inhibition of PI3K disrupts HR, and PARP blockade induces AKT activation, supporting the combination of PI3Ki and PARPi. Herein, we investigated the safety and preliminary efficacy of the PI3Ki copanlisib and the PARPi rucaparib in patients with or without alterations in HR repair pathway genes.

Year:

2025

Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.

Year:

2025

Hierarchical clustering analyses of benign, localized, and mCRPC tumors representing the expression of neuroendocrine marker genes (NE), androgen-related genes (AR), and genes related to squamous (SQUAM) differentiation

Year:

2025

Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a. 22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b. 22Rv1, SHP-77, and T cells co-cultured with AMG 757. c. 22Rv1, SHP-77, and T cells co-cultured with AMG 160.

Year:

2025

Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.

Year:

2025

Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a. 22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b. 22Rv1, SHP-77, and T cells co-cultured with AMG 757. c. 22Rv1, SHP-77, and T cells co-cultured with AMG 160.

Year:

2025

Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a. 22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b. 22Rv1, SHP-77, and T cells co-cultured with AMG 757. c. 22Rv1, SHP-77, and T cells co-cultured with AMG 160.

Year:

2025

Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.

Year:

2025

Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (65)

Meng Zhang

Assistant Professor of Urology

Emory University

UNITED STATES
View details

Rohit Mehra

University of Michigan Medical School

UNITED STATES
View details

Benedito A. Carneiro

-

UNITED STATES
View details

David A. Quigley

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Sheldon Holder

Assistant Professor

Brown University

UNITED STATES
View details

Mehmet Asim Bilen

Emory University School of Medicine

UNITED STATES
View details

Joshua Lang

Professor

University of Wisconsin-Madison

UNITED STATES
View details

Nancy Y. Greenland

-

UNITED STATES
View details

Wendy Rathmell

Professor, Department Chair

Vanderbilt University Medical Center

UNITED STATES
View details

Tamara L. Lotan

Professor

Johns Hopkins University

UNITED STATES
View details

Jiaoti Huang

Professor and Chairman

Duke Medicine

UNITED STATES
View details

Emily K. Bergsland

University of California, San Francisco

UNITED STATES
View details

Nikolaos Trikalinos

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

Alan Ashworth

University of California, San Francisco

UNITED STATES
View details

Alexander W. Wyatt

Assistant Professor

The University of British Columbia

CANADA
View details

Matthew Rettig

Professor

University of California, Los Angeles

UNITED STATES
View details

Shuang G. Zhao

University of Wisconsin-Madison

UNITED STATES
View details

Massimo Loda

Chair

Weill Cornell Medical College

UNITED STATES
View details

Lawrence True

Professor

University of Washington

UNITED STATES
View details

Li Zhang

Professor

UCSF

UNITED STATES
View details

Emily Chan

Stanford University

UNITED STATES
View details

Timothy Burns

Professor

University of Pittsburgh

UNITED STATES
View details

Henry VanBrocklin

Professor/ Director of Radiopharmaceutical Research

University of California, San Francisco

UNITED STATES
View details

Kim Chi

Chief Medical Officer

BC Cancer

CANADA
View details

Jiang He

Professor

University of Virginia

UNITED STATES
View details

David M. Wilson

University of California

UNITED STATES
View details

Devalingam Mahalingam

Associate Professor of Medicine

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Adam Olszewski

Associate Professor of Medicine

Rhode Island Hospital

UNITED STATES
View details

Michelle Badura

Lecturer

Santa Clara University

UNITED STATES
View details

Michael Haffner

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Patricia LoRusso

Yale University

UNITED STATES
View details

Renuka Sriram

University of California

UNITED STATES
View details

Raunak Shrestha

Assistant Professor

Uniformed Services University of the Health Sciences

UNITED STATES
View details

Lisa Horvath

Conjoint Professor of Medical Oncology (Genitourinary Cancer)

University of Sydney

AUSTRALIA
View details

Tomasz Michal Beer

Oregon Health & Science University

UNITED STATES
View details

Emily Egusa

University of California, San Francisco

UNITED STATES
View details

Chien-Kuang Ding

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Anil Parsram Bidkar

Assistant Professional Researcher

University of California, San Francisco

UNITED STATES
View details

Eric J. Small

University of California, San Francisco

UNITED STATES
View details

Franklin W. Huang

-

UNITED STATES
View details

Lawrence Fong

Fred Hutch Cancer Center

UNITED STATES
View details

Owen Witte

University Professor

University of California, Los Angeles

UNITED STATES
View details

Pamela N. Munster

Professor

Stanford University

UNITED STATES
View details

Brandon Chen

University of California, San Francisco

UNITED STATES
View details

Jeffrey Belkora

Associate Adjunct Professor

University of California, San Francisco

UNITED STATES
View details

Mark A. Rubin

Professor

University of Bern

SWITZERLAND
View details

Arian Lundberg

Assistant Professor at KTH Royal Institute of Technology

KTH Royal Institute of Technology

SWEDEN
View details

Jonathan Chou

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

sinan wang

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Felix Y. Feng

University of California

UNITED STATES
View details

Changhua Mu

Assistant Professional Researcher

University of California, San Francisco

UNITED STATES
View details

Christopher Evans

Professor

University of California, Davis

UNITED STATES
View details

Ana Aparicio

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Wafik S. El-Deiry

Associate Dean, Oncologic Sciences

Brown University

UNITED STATES
View details

Robert R. Flavell

University of California

UNITED STATES
View details

Mathieu Lupien

Senior Scientist

University Health Network

CANADA
View details

Shahneen Sandhu

-

AUSTRALIA
View details

Peter S. Nelson

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Y. Seo

University of California, San Francisco

UNITED STATES
View details

Terence Friedlander

University of California, San Francisco

UNITED STATES
View details

Megha Basak

University of California, San Francisco

UNITED STATES
View details

Scott C. Kogan

University of California, San Francisco

UNITED STATES
View details

kondapa Naidu Bobba

Assistant professor

University of Tennessee

UNITED STATES
View details

Mamta Parikh

Associate Professor

University of California Davis Comprehensive Cancer Center

UNITED STATES
View details

Shaolei Lu

Brown University Warren Alpert Medical School

UNITED STATES
View details